WO2023119230 - COAGULATION PATHWAY AND NICOTINAMIDE-ADENINE DINUCLEOTIDE PATHWAY MODULATING COMPOSITIONS AND METHODS OF THEIR USE
National phase entry is expected:
Publication Number
WO/2023/119230
Publication Date
29.06.2023
International Application No.
PCT/IB2022/062694
International Filing Date
22.12.2022
Title **
[English]
COAGULATION PATHWAY AND NICOTINAMIDE-ADENINE DINUCLEOTIDE PATHWAY MODULATING COMPOSITIONS AND METHODS OF THEIR USE
[French]
COMPOSITIONS DE MODULATION DE LA VOIE DE COAGULATION ET DE LA VOIE DE NICOTINAMIDE-ADÉNINE DINUCLÉOTIDE ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
L'OREAL
Inventors
WAUGH, Jacob
SHACKNAI, Jonah
Priority Data
63/292,960
22.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3421 | |
| EPO | Filing, Examination, Granting | 14042 | |
| Japan | Filing, Examination, Granting | 2210 | |
| South Korea | Filing, Examination, Granting | 2105 | |
| USA | Filing, Examination, Granting | 6090 |
Total:
27,868
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are compositions comprising (1) a physiologically effective amount (e.g., a cosmetically effective amount or therapeutically effective amount) of a coagulation pathway modulation component (CP-MC), which modulates a protein C activity (either directly, indirectly, such as through modulating protein S activity, or both), and (2) a physiologically effective amount (e.g., a cosmetically effective amount or therapeutically effective amount) of a nicotinamide-adenine dinucleotide (NAD) pathway modulation component (NADP-MC). The CP-MC can comprise vitamin K compounds, such as vitamin K1. The NADP-MC can comprise a nicotinate compound component, a niacinamide compounds component, or both. In cases, compositions include additional components/ingredients, such as a penetration enhancing component comprising one or more penetration enhancers. Also provided are methods of modulating conditions in subjects, such as the appearance of skin or the treatment/prevention of skin diseases, comprising administering such compositions or compositions comprising such components in a manner effective to achieve desired effects.[French]
L'invention concerne des compositions comprenant (1) une quantité physiologiquement efficace (par exemple, une quantité cosmétiquement efficace ou une quantité thérapeutiquement efficace) d'un composant de modulation de la voie de coagulation (CP-MC), qui module une activité de protéine C (soit directement, indirectement, par exemple par modulation de l'activité de la protéine S, ou les deux), et (2) une quantité physiologiquement efficace (par exemple, une quantité cosmétiquement efficace ou une quantité thérapeutiquement efficace) d'un composant de modulation de la voie de nicotinamide-adénine dinucléotide (NADP-MC). Le CP-MC peut comprendre des composés de vitamine K, tels que la vitamine K1. Le NADP-MC peut comprendre un composant de composé de nicotinate, un composant de composés de niacinamide, ou les deux. Dans certains cas, les compositions comprennent des composants/ingrédients supplémentaires, tels qu'un composant améliorant la pénétration comprenant un ou plusieurs activateurs de pénétration. L'invention concerne également des procédés de modulation d'états chez des sujets, tels que l'aspect de la peau ou le traitement/la prévention de maladies de la peau, comprenant l'administration de telles compositions ou de telles compositions comprenant de tels composants d'une manière efficace pour obtenir des effets souhaités.